Clinical-epidemiologic behavior of malignant periampullary tumors diagnosed in Gastroenterology
Keywords:
periampullary tumors, cholangiocarcinoma, ampulloma, pancreatic cancerAbstract
Introduction: Malignant tumors located in the periampullary region can be ampullary, biliary, pancreatic or duodenal and are a health problem due to their high mortality. Their etio-pathogenesis involves many risk factors, whose clinic and epidemiological behavior is unknown by the population of Matanzas.
Objective: To determine the clinical-epidemiological behavior of malignant periampullary tumors.
Materials and methods: A descriptive, prospective study was conducted in 34 patients with diagnosis of malignant periampullary tumors, treated in the Gastroenterology Service of the Clinical-Surgery University Hospital Comandante Faustino Perez Hernandez, of Matanzas, from January to December 2021. Variables such as age group, sex, risk factors and personal pathological history, time of evolution of symptoms and tumor location were studied. The results were collected in a data collection form.
Results: Male sex and the 50-69 years age group predominated. The most frequent risk factors were coffee consumption, smoking and diabetes mellitus. Jaundice was the most frequent symptom. Most of the patients started symptoms one to three months before the diagnosis. Pancreatic cancer was the most frequent.
Conclusions: Periampullary tumors predominated in the population older than 50 years. Toxic habits were the most common risk factors. Pancreatic cancer had a higher incidence. Clinical behavior was related to the location of the lesion, the time of evolution of the symptoms, and the risk factors that predominated.
Downloads
References
2. Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol [Internet]. 2016 [citado 17/03/2021];13(5):261-80. Disponible en: https://doi.org/10.1038/nrgastro.2016.51
3. Serra Pueyo J. Neurofisiología gastroduodenal y técnicas diagnósticas [Internet]. Andalucía: Sociedad Andaluza de Patología Digestiva; 2017 [citado 17/03/2021];40(5). Disponible en: https://www.sapd.es/documents/cursos/MPC_Tema5.pdf
4. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557-88. DOI: 10.1038/s41575-020-0310-z.
5. Dirección de Registros Médicos y Estadísticas de Salud. Anuario estadístico de salud 2020 [Internet]. La Habana: Ministerio de Salud Pública; 2021 [citado 17/06/2021]. Disponible en: https://salud.msp.gob.cu/wp-content/Anuario/Anuario-2020.pdf
6. Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology. 2018;68(1):113-26. Citado en PubMed; PMID: 29360137.
7. Xiong J, Xu W, Bian J, et al. Aspirin use is associated with a reduced risk of cholangiocarcinoma: a systematic review and meta-analysis. Cancer Manag Res. 2018;10:4095-104. DOI: 10.2147/CMAR.S173197.
8. European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut [Internet]. 2018 [citado 17/06/2021];67(5):789-804. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/PMC5890653/
9. Alonso Soto J, Martínez Piti A, Díaz Rondón B, et al. Caracterización de los pacientes con tumores de la vía biliar mediante colangiopancreatografía retrógrada endoscópica. Rev Cubana Med [Internet]. 2016 [citado 17/06/2021];55(2):141-9. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232016000200005
10. Strijker M, Belkouz A, Van der Geest LG, et al. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol [Internet]. 2019 [citado 17/06/2021];58(7):1048-55. Disponible en: https://www.tandfonline.com/doi/full/10.1080/0284186X.2019.1590634
11. Gallardo Arizaga HA, Cedeño Avilés GA, Revelo Hidalgo KO, et al. Utilidad de CPRE en pancreatitis biliar. Recimundo [Internet]. 2019 [citado 02/01/2020];3(3 ESP):198-217. Disponible en: http://recimundo.com/index.php/es/article/view/597
12. Kcam E, Tavara F, Milla R, et al. Tratamiento del ampuloma con cirugía de Whipple. Reporte del primer caso en el hospital regional de Tumbes. Rev Gastroenterol Perú [Internet]. 2018 [citado 17/06/2021];38(2):187-91. Disponible en: http://www.scielo.org.pe/scielo.php?pid=S1022-51292018000200012&script=sci_arttext&tlng=en
13. Clements O, Eliahoo J, Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol [Internet]. 2020 [citado 02/01/2020];72(1):95-103. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0168827819305434
14. Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist [Internet]. 2016 [citado 17/06/2021];21(5):594-9. Disponible en: https://academic.oup.com/oncolo/article/21/5/594/6401575
15. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial - mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69-84. Citado en PubMed; PMID: 30459476.
16. Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212-26. DOI: 10.1016/j.tcb.2018.12.001.
17. Fabris L, Perugorria MJ, Mertens J, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 2019;39(S1):63-78. Citado en PubMed; PMID: 30907492.
18. Montiel Roa AJ, Fleitas Oviedo DJ, Vargas Velázquez JMA. Frecuencia del tratamiento quirúrgico curativo de las neoplasias periampulares. Experiencia en base a 122 casos. Rev Cir Parag [Internet]. 2016 [citado 17/06/2021];40(2):12-8. Disponible en: https://doi.org/10.18004/sopaci.noviembre.12-18
19. Estrella Díez E, Álvarez Higueras FJ, Carballo Álvarez F. Cáncer de la vía biliar y del páncreas. Medicine [Internet]. 2016 [citado 17/06/2021];12(8):430-41. Disponible en: http://www.medicineonline.es/es-cancer-via-biliar-del-pancreas-articulo-S0304541216300166
20. Romaguera Barroso D, Saint Surín K, León Goire WL, et al. Caracterización de pacientes con neoplasias primarias del segmento hepatobiliopancreático. Medisan [Internet]. 2015 [citado 17/06/2021];19(2):158-68. Disponible en: https://medisan.sld.cu/index.php/san/article/view/137
21. Sánchez-García NL, Moure-Díaz A, Labrada-Moreno LM, et al. Pacientes con tumores malignos del segmento biliopancreático atendidos en el Instituto de Gastroenterología. Arch cuba gastroenterol [Internet]. 2021 [citado 17/06/2021];2(1):e55. Disponible en: https://revgastro.sld.cu/index.php/gast/article/view/53
22. Ziani L, Chouaib S, Thiery J. Alteration of the antitumor immune response by cancer-associated fibroblasts. Front Immunol. 2018;9:414. Citado en PubMed; PMID: 29545811.
23. Muñoz-Garrido P, Rodríguez PM. The jigsaw of dual hepatocellular - intrahepatic cholangiocarcinoma tumours. Nat Rev Gastroenterol Hepatol. 2019;16(11):653-5. Citado en PubMed; PMID: 31296968.
Downloads
Published
How to Cite
Issue
Section
License
All content published in this journal is Open Access, distributed under the terms of the CC BY-NC 4.0 License.
It allows:
- Copy and redistribute published material in any medium or format.
- Adapt the content.
This will be done under the following terms:
- Attribute the authors' credits and indicate whether changes were made, in which case it must be in a reasonable way.
- Non-commercial use.
- Recognize the journal where it is published.
The copyrights of each article are maintained, without restrictions.
Guidelines to authors
